141 results about "Enterocyte" patented technology

The invention discloses an anti-neurodegeneration exosome composition as well as a preparation method and application thereof. The anti-neurodegeneration exosome composition is prepared from the following components in parts by mass: 5 to 25 parts of human exfoliated deciduous tooth stem cell exosome, 25 to 85 parts of plant-derived exosome-like nano-vesicles, 12 to 10 parts of ginsenoside Rg, 2 to 10 parts of curcumin and 10 to 20 parts of auxiliary materials. The anti-neurodegeneration exosome composition contains a large amount of cell factors, growth factors, miRNA, mRNAs and other components, is easy to fuse with cell membranes of intestinal epithelial cells, can selectively deliver bioactive substances to recipient cells through a blood-brain barrier, carries out information transmission among different cells, regulates signal transduction among the cells, and has a good anti-neurodegeneration effect. The effects of resisting oxidation, resisting inflammation, resisting aging and the like are achieved.

This invention discloses a strain of *Lactobacillus plantarum* Grx402 with the ability to promote intestinal absorption of short-chain fatty acids. *Lactobacillus plantarum* Grx402 was isolated from the intestines of long-lived individuals in Bama, Guangxi (CGMCC No. 28585). Using a Caco-2 cell model to construct an intestinal absorption model of short-chain fatty acids (SCFAs), it was found that *Lactobacillus plantarum* Grx402 can promote the absorption and transport of acetic acid, propionic acid, and butyric acid by intestinal epithelial cells, exhibiting excellent ability to promote intestinal absorption of short-chain fatty acids. It can be used to prepare dairy products or beverages that promote the intestinal absorption of short-chain fatty acids.

The invention belongs to the technical field of marine microorganisms, and discloses an application of Propionibacterium fredenreici subsp. Schermani NHNK-616 in preparation of a product for improving macular retinae, the Propionibacterium fredenreici subsp. Schermani NHNK-616 is preserved in the China Center for Type Culture Collection on July 1, 2024, and the preservation number of the Propionibacterium fredenreici subsp. Schermani NHNK-616 is CCTCC NO: M 20241429. The invention further discloses a preparation method of the Propionibacterium fredenreici subsp. Schermani NHNK-616. The inventor finds that the NHNK-616 has the functions of improving the oxidation resistance of the retina, increasing the retinal barrier, reducing retinal neovascularization, reducing retinal inflammation and the like, in addition, an NHNK-616 thallus biological membrane can improve the colonization capacity of nasal epithelial cells and intestinal epithelial cells, and the NHNK-616 can be used for preparing products for improving the retina macular.

The invention discloses a lipid nanoparticle, a targeted lipid nanoparticle, and a preparation method and application thereof. The lipid nanoparticle has a core-shell structure, the core is formed by PLGA nanoparticles containing drug molecules, and the shell is formed by raw materials including phospholipid, cholesterol and a modification material; wherein the PLGA nanoparticles containing the drug molecules are formed by raw materials comprising PLGA and the drug molecules; the mass ratio of the PLGA to the phospholipid is (1-5): 1; the mass ratio of the phospholipid to the cholesterol is (3-10): 1, and the mass ratio of the phospholipid to the modification material is (3-10): 1; the drug molecules are selected from one or more of insoluble drugs, water-soluble drugs, genes and proteins; and the modification material is PEG-DSPE (Polyethylene Glycol Distearoyl The hardness of the lipid nanoparticles can be regulated and controlled, and cellular uptake can be improved by regulating and controlling the hardness; the targeted lipid nanoparticles can better improve cellular uptake, promote intestinal epithelial cell absorption and improve oral curative effect.

The invention discloses application of leuconostoc mesenteroides subsp. Mesenteroides in improvement of coronary heart disease and sclerotin, and belongs to the technical field of marine microorganisms. The invention discloses a leuconostoc mesenteroides subsp. Mesenteroides NHNK-613, which is preserved in the China Center for Type Culture Collection on July 1, 2024, and the preservation number of the leuconostoc mesenteroides subsp. Mesenteroides NHNK-613 is CCTCC (China Center for Type Culture Collection) NO: M 20241431. The NHNK-613 has the capabilities of adsorbing calcium ions, up-regulating intestinal epithelial cell calcium and vitamin D absorption and transfer related gene expression, promoting intestinal absorption and transfer of calcium ions, promoting intestinal tract conversion of 1, 25-dihydroxy vitamin D3, promoting myocardial cell repair, regulating bone metabolism related genes, promoting osteoblast repair and promoting vascular endothelial cell repair. The composition can be used for preparing products for improving coronary heart disease and sclerotin.

The invention provides a composition for promoting differentiation of intestinal immune cells as well as a preparation method and application of the composition. According to the composition, 1, 3-dioleic acid-2-palmitic acid triglyceride and breast milk oligosaccharide are used in a combined manner, so that monocytes can be effectively promoted to differentiate into intestinal macrophages, and inflammation is reduced to a certain extent. After the monocytes are differentiated into the intestinal macrophages, the intestinal immune homeostasis and intestinal microbiota inflammatory response can be regulated, so that the mucosal immune homeostasis and intestinal epithelial cell barrier function are maintained. Therefore, the composition provided by the invention can improve the intestinal immune barrier by promoting the monocytes to differentiate into the intestinal macrophages, and provides a new thought for improving the early intestinal barrier of infants through nutritional supplement.

The invention discloses an application of engineered citrobacter freundii in fermentation synthesis of a stable body. The engineered citrobacter freundii is citrobacter freundii overexpressing a polyphosphate kinase gene Ppk1. The stable body prepared by fermenting the engineered citrobacter freundii is rich in polyphosphates and polyamines, particularly, the content of the polyamines can be up to 21wt%, the polyphosphates in the stable body can store the polyamines in an ionic bond combination mode, the combined polyamines are insoluble in water, a natural anion coating is generated, and the stability of the stable body is improved. And the sustained-release tablet is not easily taken by intestinal epithelial cells, so that the sustained-release tablet has a certain sustained-release effect. The medicine prepared by taking the compound as a main active ingredient shows a remarkable curative effect in ulcerative colitis treatment, has the comprehensive effects of reducing oxidative stress, enhancing the anti-inflammatory ability of a body and regulating immunity, is suitable for patients of all ages, and has outstanding application value and market prospect.

The invention discloses an application of knocking down intestinal epithelial cells Mysm1 in increasing secretion of 5-HT by the intestinal epithelial cells. The invention provides application of a substance capable of inhibiting Mysm1 gene expression and / or activity in promoting intestinal tract / intestinal epithelial cells to secrete 5-hydroxytryptamine. According to the invention, the synthesis amount of the 5-HT in the intestinal tract can be manually regulated and controlled, so that the functions of the 5-HT in intestinal brain communication, intestinal tract barrier and the like are regulated and controlled; a product for promoting intestinal epithelial cells to secrete 5-hydroxytryptamine can be prepared, so that the 5-HT function is productized, and the use is convenient.

The invention relates to the technical field of marine microorganisms, in particular to application of combined lactobacillus salivarius in preparation of products for improving metabolism of alcohol and uric acid, the combined lactobacillus salivarius NHNK-603 is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 2024416. Experiments show; the NHNK-603 has the effects of inhibiting the growth of klebsiella pneumoniae, inhibiting the production of alcohol, agglutinating the klebsiella pneumoniae, inhibiting the virulence gene of the klebsiella pneumoniae, promoting alcohol metabolism, reducing alcohol damage, tolerating alcohol, degrading uric acid, inhibiting the activity of xanthine oxidase, promoting uric acid excretion, promoting the proliferation of Alistipes indinctus and synthesizing hippuric acid; the thallus biofilm increases the function of colonization on mucoprotein and intestinal epithelial cells, and can be applied to preparation of products for improving metabolism of alcohol and uric acid.

The invention relates to lactobacillus plantarum-derived inorganic polyphosphate and application thereof in promoting cell proliferation. The preparation method of the lactobacillus plantarum-derived inorganic polyphosphate comprises the following step: extracting from lactobacillus plantarum by using glass milk. According to the invention, long-chain PolyP (PolyPLp) with the chain length of about 250 phosphate residues is extracted and purified from lactobacillus plantarum by using glass milk. And the effect of promoting cell proliferation is proved. An IL-1beta-induced Caco-2 intestinal epithelial cell barrier injury model is utilized, it is found that PolyP has the function of relieving intestinal inflammation, the effect of PolyP has chain length dependence, and the action effect of PolyPLp is optimal.

The invention discloses an application of a pyrrosia lingua aqueous extract in preparation of a medicine for preventing and treating radioactive intestinal injury. Radioactive intestinal injury is a common complication of ionizing radiation, and has main pathological characteristics of intestinal mucosal barrier destruction, excessive release of inflammatory factors, increase of oxidative stress level and hematopoiesis and immune function inhibition. At present, no effective and safe prevention and treatment medicine is available. It is found for the first time that the pyrrosia lingua aqueous extract can inhibit expression (IL-6, TNF-alpha and IL-1beta) of inflammatory factors of radiation-induced MODE-K cells and relieve the oxidative stress level (malondialdehyde (MDA) is reduced, and the content of superoxide dismutase (SOD) and glutathione (GSH) is increased). In animal experiments, the pyrrosia lingua aqueous extract can reduce the levels of TNF-alpha and IL-1beta inflammatory factors in serum of irradiated mice and improve oxidative stress disorders such as MDA increase, SOD and GSH decrease and the like; the reduction of leukocytes and lymphocytes is relieved; the length of intestinal villus is promoted and recovered; the proportion of Ki67 positive cells in a crypt region is increased, so that the regeneration capacity of intestinal epithelial cells is enhanced. The pyrrosia lingua aqueous extract disclosed by the invention provides an experimental basis and an application prospect for developing a novel medicine for preventing and treating the radioactive intestinal injury.

A probiotic and prebiotic-embedded synbiotic system for targeted delivery and colonization of functions, comprising a probiotic core; an inner layer of protein-polysaccharide / oligosaccharide complex wrapped around the probiotic surface, which acts as both an adhesion promoter, promoting the attachment of probiotics to the intestinal epithelial cells, and as a prebiotic, promoting the growth of probiotics upon release; and an outer layer of a natural emulsifying system on the synbiotic complex, which minimizes water infiltration, thereby effectively embedding and protecting the probiotics. The present synbiotic system is suitable for production in powder form using freeze-drying technology, and is suitable as a dietary supplement or for addition to any food in dry powder form. The system has the ability to bioconvert soy isoflavones and release bioactive phenolic acids from grains to promote body health.

The present invention provides a kind of radix schizonepetae extract for treating ulcerative colitis and its preparation method and application, and relates to the field of biomedicine technology. The preparation method of the radix schizonepetae extract of the present invention comprises: soaking radix schizonepetae in water, heating and boiling, condensing and refluxing, filtering, and collecting the filtrate, which is the radix schizonepetae extract. The radix schizonepetae extract of the present invention can reduce collagen deposition and intestinal epithelial cell apoptosis in the colon epithelium of ulcerative colitis, has the effect of downregulating the abnormally high expression of genes and proteins such as N-cadherin, IntegrinA1, Vinculin, TGF-β2, Srcin, etc. in the colon tissue of ulcerative colitis, reduces colon fibrosis and inflammatory damage, protects the barrier function of the colon epithelium, and has the effect of inhibiting the overexpression of Wnt 5A / B and β-Catenin proteins caused by DSS, and alleviates colon fibrosis, thereby achieving the effect of treating ulcerative colitis and alleviating colon fibrosis.

The application discloses a kind of compositions for treating radiation enteropathy and application thereof, belong to medical technology field.The composition includes the following components: anemarrhena asphodeloides B4, obakunine, berberine, aesculetin, fraxinellone and fraxinellin.The composition has no toxic side effects, has good safety, can reduce the inflammatory infiltration of intestinal epithelial cells, reduce intestinal epithelial cell apoptosis, protect intestinal barrier and protect intestinal oxidative damage by regulating NF-κB, Caspase 9 / 3 and NRF2 pathway, and then multi-component, multi-pathway jointly play the efficacy of treating radiation enteropathy.The problem that there is no effective drug for treating radiation enteropathy in the prior art is solved.

The invention relates to the technical field of functional food preparation, in particular to a composition capable of improving colitis and a preparation method thereof, and the composition comprises glutamine, a composite plant extract, a zinc source and soluble dietary fibers. Wherein the compound plant extract comprises hericium erinaceus extract, ginseng extract and astragalus extract; the zinc source is zinc glycinate, zinc gluconate and the like; the soluble dietary fiber is fructo-oligosaccharide, inulin, galactomannan oligosaccharide and the like. The preparation method comprises the following steps: directly carrying out dry mixing or carrying out fluidized bed granulation on glutamine to obtain particles A, mixing the composite plant extract and the dietary fibers with ethanol, carrying out spray drying to obtain particles B, and carrying out three-dimensional mixing on the particles B and the zinc source. The composition can maintain the homeostasis of intestinal epithelial cells, reduce oxidative stress and inflammatory response, promote mucosal repair and effectively improve ulcerative colitis, Crohn's disease and chemoradiotherapy-related intestinal mucositis through multi-target action.

The use of a probiotic, particularly the Enterococcus faecium strain NCIMB 10415 which is named SF68® as probiotic active ingredient, in combination with butyric acid or a salt thereof to increase the enterocyte's health and consequently the wellness of pets and livestock is described.

The invention discloses application of an aromatic hydrocarbon receptor stimulant in preparation of a medicine for treating diarrhea of weaned piglets and / or inhibiting inflammation, and belongs to the field of biological medicine. According to the present invention, with the PAS-B structural domain of the AHR as the target, the virtual screening technology, the target verification test and the weaned piglet diarrhea pharmacodynamic evaluation test are performed to determine the arctigenin as the AHR strong agonist and the anti-inflammatory drug, and the arctigenin has the good treatment effect on the weaned piglet diarrhea. Experimental results show that 10 mg / kg of arctigenin can significantly relieve diarrhea and hemafecia symptoms of weaned piglets, reduce the content of inflammatory factors in serum and intestinal tissues and improve the intestinal structure of weaned piglets, has no significant cytotoxicity, hepatorenal toxicity and intestinal epithelial cell growth inhibition effect, and can be used for preparing a feed additive for weaned piglets. The compound can be used for preparing medicines for treating diarrhea of weaned piglets. The invention provides a new raw material medicine for treating diarrhea of weaned piglets, and has great economic value and wide application prospect.

The invention discloses an oral drug delivery system with a double-emulsion structure and application of the oral drug delivery system in preparation of drugs for treating premature ovarian insufficiency, and belongs to the technical field of biological medicines. The oral drug delivery system comprises droplet particles formed by wrapping an MSCs conditioned culture medium with an oil-phase solvent, and exosomes uniformly distributed on the outer surfaces of the droplet particles, so that a double-emulsion structure is formed. Water-soluble MSC-CM is wrapped by a water-in-oil-in-water method to form a double-emulsion structure, so that water-soluble protein enters a human body to be absorbed in an oral manner. The MSC-CM composite has good structural stability and viscoelasticity, the particle size range is about 10-50 microns, contact with intestinal epithelial cells can be increased, meanwhile, the skeleton of the intestinal epithelial cells can be changed, expression of tight junction protein of the intestinal epithelial cells can be lowered, tight junction barriers of the intestinal epithelial cells can be opened, and therefore the bioavailability of MSC-CM is improved, and the MSC-CM composite has a good application prospect. The effect of treating the POI is achieved.

The invention discloses application of knockout or inhibition of intestinal epithelium Ufbp1 gene expression in preparation of medicines for preventing and / or treating obesity, and belongs to the technical field of biological medicines. In order to solve the problems of limited effect, many side effects and the like of the existing obesity treatment means, the invention provides Ufbp1 specifically expressed by intestinal epithelial cells as a new anti-obesity intervention target for the first time. By knocking out or inhibiting intestinal epithelium Ufbp1, weight gain, adipose tissue accumulation, hyperlipidemia, liver fatty degeneration and insulin resistance induced by high fat diet can be effectively resisted. The action mechanism is related to influence on secretion of intestinal apolipoprotein ApoB48 / ApoA1 and further regulation and control of whole body lipid metabolism. The invention provides a clear target and theoretical basis for developing novel anti-obesity therapies such as small-molecule inhibitors and nucleic acid drugs of targeted intestinal epithelium Ufbp1, and has important clinical transformation prospects.

The invention discloses targeted probiotic dietary powder for conditioning intestinal microecology and a preparation method of the targeted probiotic dietary powder. According to the invention, the micro-ecological health of intestinal tracts is obviously improved through a triple synergistic mechanism. The core probiotic combination directly acts on the key link of intestinal flora imbalance. Lactobacillus plantarum LP-12 inhibits excessive release of intestinal inflammatory factors and alleviates intestinal mucosa damage. The bifidobacterium bifidum TMC3115 enhances tight connection of intestinal epithelial cells and repairs a physical barrier; the Witzia ciliaris MKSWC01 can degrade endotoxin and block the chain reaction of chronic inflammation. Meanwhile, the fucoidin and the galactooligosaccharide are used for accurately feeding the probiotics and enhancing the colonization capability of the probiotics in a colon mucus layer, so that long-acting protection is formed. L-glutamine provides basic nutrition required by intestinal mucosa regeneration, and resistant dextrin continuously generates short-chain fatty acid to maintain a weak acid environment of colon, so that healthy flora ecology is comprehensively reconstructed.

The present invention discloses a method for constructing an animal model of ankylosing spondylitis and chronic enteritis. By using proteoglycan PG immune induction and sodium dextran sulfate chemical induction methods, an animal model is established that simulates the coexistence of ankylosing spondylitis and chronic enteritis in terms of symptoms, imaging changes, and pathological characteristics. The model mice exhibit imaging changes similar to those of human ankylosing spondylitis, such as sacroiliac joint bone erosion and sclerosis, narrowing and roughening of the joint space, and worm-eaten changes. Furthermore, they exhibit pathological changes similar to those of human chronic enteritis, such as intestinal epithelial cell destruction, glandular disorder, crypt structure destruction, goblet cell reduction, and inflammatory cell infiltration. This model can be used to study the interaction mechanism between the two diseases, explore new therapeutic targets, and help evaluate the potential application of new drugs in the treatment of ankylosing spondylitis and chronic enteritis, providing an important tool for mechanism research and drug development of such co-morbidities.

The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.

The invention relates to the technical field of microorganisms, in particular to bifidobacterium animalis and application of the bifidobacterium animalis to preparation of products for improving heart rate, bone and blood pressure. The bifidobacterium animalis is bifidobacterium animalis subsp. Lactis NHNK-625, and is preserved in the China Center for Type Culture Collection on February 28, 2025, and the preservation number of the bifidobacterium animalis is CCTCC NO: M 2025325. The traditional Chinese medicine composition has the effects of adsorbing calcium ions, promoting calcium absorption of intestinal epithelial cells and physiological action of vitamin D, promoting calcium ion transport of the intestinal epithelial cells, promoting activation and utilization of vitamin D, promoting myocardial cell repair, regulating osteoblast bone metabolism, promoting osteoblast repair and promoting vascular endothelial cell repair. The composition can be used for preparing products for improving heart rate, sclerotin and blood pressure.

The invention relates to the technical field of probiotics, in particular to intestinal tract source pediococcus acidilactici of Yanqu county in Tibet and fat reducing application thereof. The pediococcus acidilactici disclosed by the invention is preserved in the China General Microbiological Culture Collection Center on April 29, 2025, and the preservation number is CGMCC NO.34406; the strain has the characteristics of acid resistance, cholate resistance and stress resistance, and has high survival rate and planting efficiency; the strain is free of hemolysis, free of toxic factors and high in safety; the strain can secrete short-chain fatty acid and antibacterial peptide, inhibit pathogenic bacteria and promote intestinal barrier repair; short-chain fatty acid generated by metabolism of most of carbon water by the strain can be directly absorbed by intestinal epithelial cells, and can be used as an energy substance to replace partial glucose demand, so that the metabolism energy consumption is reduced, the energy conversion rate of feed is improved, the feed conversion is promoted, and the effects of reducing fat and weight and improving the non-alcoholic fatty liver disease are achieved.

The invention relates to a mouse model for specifically inducing apoptosis, necrosis and pyroptosis of intestinal epithelial cells and a construction method thereof, the method comprises the following steps: designing sgRNA targeting a first exon and a second exon of a Rosa26 gene, the sequence of the sgRNA being as shown in SEQ ID NO: 1 and SEQ ID NO: 2; the method comprises the following steps: constructing an expression cassette carrying fusion genes of Gsdmd-HBD, Caspase8-ERT2 and Mlkl-ERT2, and connecting the fusion genes through a Linker sequence as shown in SEQ ID NO: 12; integrating the expression cassette between a first exon and a second exon of a Rosa26 site of a mouse by adopting a CRISPR / Cas9 technology through a homologous recombination mode to obtain a gene editing mouse; a gene editing mouse with positive PCR amplification and sequencing identification is mated with a Vilin-cre < + / -> mouse, and the mouse model of which the intestinal epithelial cells specifically express the fusion gene is obtained. The mouse model can specifically induce single-type intestinal epithelial cell death, and avoids non-specific signal activation and complex environment disturbance accompanied by a traditional method to the greatest extent.

The invention relates to an application of an anti-CD73 monoclonal antibody combined with an Adora1 inhibitor in treatment of intestinal fibrosis. In the invention, the inventor finds that long-term WD generates GSDME-mediated pyroptosis by inducing intestinal epithelial cells and releases a large amount of intracellular molecules HMGB1 and ATP, the HMGB1 promotes CD39 + CD73 + CD8 + T cell amplification, the group of cells catalyzes extracellular ATP into Ado, and finally the Ado activates intestinal fibroblasts through a receptor Adara1 so as to participate in a complex intestinal fibrosis process. Based on this, the inventor finds that the CD-related intestinal fibrosis can be effectively improved by blocking the generation of intestinal adenosine or / and inhibiting the receptor of the intestinal adenosine, and a combined medicine, namely the anti-CD73 monoclonal antibody combined Adara1 inhibitor, is researched and developed, can be used for treating the CD-related intestinal fibrosis, and has important clinical application value.

The invention belongs to the technical field of gene engineering, and provides Hsp60 receptor targeted recombinant lactobacillus plantarum as well as a construction method and application thereof, lactobacillus plantarum is taken as a host, pPG612 is taken as an expression vector, and CsgB gene or CsgF gene is expressed. The two engineering probiotics can express target protein and can be stably expressed on the surfaces of thalli, the AB.9 intestinal epithelial cells can be effectively adhered, and the adhesion and invasion of the A.veronii to the AB.9 cells can be inhibited. And secondly, the engineering probiotics LP-pPG-CsgB and LP-pPG-CsgF can promote the proliferation of dendritic cells, T lymphocytes and B lymphocytes, and improve the IgT secretion of intestinal mucus. The engineering bacteria can be competitively combined with an intestinal epithelial cell Hsp60 receptor, down-regulate p65 expression, inhibit NF-kappa B signal channel activation, regulate intestinal tight junction protein redistribution and down-regulate proinflammatory factor expression through a TLR4 / TLR5 dependent NF-kappa B signal channel, and the engineering bacteria can increase the abundance of effective microbial communities in the intestinal tract of the snakeheaded fish, so that the growth of the snakeheaded fish is promoted, and the growth of the snakeheaded fish is promoted. And the flora can transfer, mediate and activate immune response through a feeding environment.

The application belongs to the technical field of microorganisms, and discloses a propionic acid-producing propionic acid bacteria NHNK-621 and application of the propionic acid bacteria in preparation of products for improving constipation and memory, the bacteria strain has been preserved in the China Center for Type Culture Collection on November 25, 2024, and the number is CCTCC NO: M 20242631. The propionic acid bacteria NHNK-621 provided by the application has the functions of promoting 5-HT secretion, up-regulating intestinal aquaporin and brain-derived neurotrophic factor genes, metabolically producing gamma-aminobutyric acid, inhibiting growth of Candida albicans, inhibiting hypha formation of Candida albicans, combining with hypha of Candida albicans, up-regulating intestinal defensin and mucin gene expression, in addition, the bacterial biofilm can increase the colonization ability to intestinal epithelial cells, and can be used for preparing products for improving constipation and memory.

The invention relates to an insulin-loaded hybrid nano-vesicle as well as a preparation method and application thereof. The hybrid nano-vesicle is obtained by hybridizing a milk-derived exosome and an insulin-loaded liposome. The milk-derived exosome and the liposome are creatively hybridized and used for co-loading and delivering insulin, the hybridized nano-vesicle can survive in a severe environment of gastrointestinal tracts and protect wrapped insulin, in intestinal tracts, the hybridized nano-vesicle interacts with FcRn on intestinal epithelial cells through surface IgG and triggers transendocytosis, and in addition, the exosome and the liposome can be used for co-loading and delivering insulin. The hybridized nano-vesicles have the advantages that a lysosome degradation pathway is avoided, then the hybridized nano-vesicles are effectively accumulated in the liver through portal veins, insulin is released in the liver to regulate blood sugar, and the hybridized nano-vesicles can be used for preparing insulin oral preparations.

The invention discloses a tilmicosin nanostructure lipid carrier and a preparation method thereof. The preparation method comprises the following steps: swelling poloxamer 188 in distilled water to serve as a water phase; the preparation method comprises the following steps: mixing and melting stearic acid and oleic acid, sequentially adding tilmicosin and Tween 80, and stirring to form an oil phase; controlling the water phase and the oil phase at the same temperature, adding the oil phase into the water phase, shearing at a high speed, and homogenizing at a high pressure to obtain a pre-emulsion; and mixing the pre-emulsion with water and then carrying out secondary high-speed shearing. The carrier can keep good stability under the acidic condition, can significantly improve the oral bioavailability of tilmicosin in piglet bodies, can promote cell uptake, and can reduce the efflux effect of a drug transporter, thereby effectively improving the efficiency of tilmicosin entering intestinal epithelial cells. In addition, the carrier can well cover the unpleasant odor and bitter taste of the medicine, the palatability of tilmicosin is improved, and the influence of tilmicosin on pig ingestion is avoided.